All In Biotech

Drug Trial Radar · NCT07024823

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

A Phase I Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 Following Single and Multiple Ascending Dose Administration in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes, to Assess Home Measurements of Creatinine in a Prospective, Non-Interventional Cohort; and to Assess the Effect of Multiple Doses of AZD4248 on the Pharmacokinetics of Oral Midazolam and Metformin in an Open-Label, Fixed Sequence Design in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Jan 29, 2027

Study completion Jan 29, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.

Conditions

  • Chronic Kidney Disease

Interventions

  • AZD4248Drug

    AZD4248 will be administered orally.

  • PlaceboDrug

    Placebo will be administered orally.

  • AZD4248Drug

    AZD4248 will be administered via IV infusion.

  • PlaceboDrug

    Placebo will be administered via IV infusion.

  • MidazolamDrug

    Midazolam will be administered orally.

  • MetforminDrug

    Metformin will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days)
  2. Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurementsTime frame: Day 1 to Day 169
  3. Part E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  4. Part E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  5. Part E: Maximum observed drug concentration (Cmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  6. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  7. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  8. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  9. Part E: Terminal elimination half-life (t½λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  10. Part E: Terminal rate constant (λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  11. Part E: Time to reach maximum observed concentration (tmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  12. Part E: AUCinf for metforminTime frame: Days 2-4, 6, and 7-16
  13. Part E: AUClast for metforminTime frame: Days 2-4, 6, and 7-16
  14. Part E: Cmax for metforminTime frame: Days 2-4, 6, and 7-16
  15. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 2-4, 6, and 7-16
  16. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 2-4, 6, and 7-16
  17. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 2-4, 6, and 7-16
  18. Part E: Renal clearance (CLR) for metforminTime frame: Days 2-4, and 6-8
  19. Part E: t½λz for metforminTime frame: Days 2-4, 6, and 7-16
  20. Part E: λz for metforminTime frame: Days 2-4, 6, and 7-16
  21. Part E: tmax for metforminTime frame: Days 2-4, 6, and 7-16

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Ann Arbor, Michigan · Active not recruiting

  • Research Site

    Saint Paul, Minnesota · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.